Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
80% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. QLTI: No Debt )
QLTI' s 10-Year Cash to Debt Range
Min: 0.74   Max: No Debt
Current: No Debt

Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
83% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. QLTI: No Debt )
QLTI' s 10-Year Interest Coverage Range
Min: 24.57   Max: 9999.99
Current: No Debt

24.57
9999.99
F-Score: 2
Z-Score: 24.57
M-Score: -3.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -15.76
QLTI's ROE (%) is ranked higher than
73% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. QLTI: -15.76 )
QLTI' s 10-Year ROE (%) Range
Min: -69.34   Max: 39.3
Current: -15.76

-69.34
39.3
ROA (%) -15.18
QLTI's ROA (%) is ranked higher than
73% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. QLTI: -15.18 )
QLTI' s 10-Year ROA (%) Range
Min: -64.76   Max: 27.43
Current: -15.18

-64.76
27.43
ROC (Joel Greenblatt) (%) -69.60
QLTI's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. QLTI: -69.60 )
QLTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -521.91   Max: 55.42
Current: -69.6

-521.91
55.42
EBITDA Growth (%) 4.00
QLTI's EBITDA Growth (%) is ranked higher than
84% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. QLTI: 4.00 )
QLTI' s 10-Year EBITDA Growth (%) Range
Min: -34.8   Max: 80.4
Current: 4

-34.8
80.4
EPS Growth (%) 41.50
QLTI's EPS Growth (%) is ranked higher than
96% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. QLTI: 41.50 )
QLTI' s 10-Year EPS Growth (%) Range
Min: -67.1   Max: 114.2
Current: 41.5

-67.1
114.2
» QLTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

QLTI Guru Trades in Q1 2013

Jim Simons 125,261 sh (+810.06%)
» More
Q2 2013

QLTI Guru Trades in Q2 2013

Jim Simons 118,564 sh (-5.35%)
» More
Q3 2013

QLTI Guru Trades in Q3 2013

Jim Simons 93,664 sh (-21%)
» More
Q4 2013

QLTI Guru Trades in Q4 2013

Jim Simons 115,164 sh (+22.95%)
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2011-09-30 Sold Out 0.004%$5.65 - $7.57 $ 5.92-14%0
Michael Price 2011-06-30 Sold Out 0.14%$6.75 - $8.52 $ 5.92-21%0
Charles Brandes 2011-06-30 Reduce -55.08%0.01%$6.75 - $8.52 $ 5.92-21%79000
Charles Brandes 2011-03-31 Reduce -35.45%0.01%$6.62 - $8.5 $ 5.92-17%175850
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
QLTI's P/B is ranked higher than
86% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. QLTI: 1.90 )
QLTI' s 10-Year P/B Range
Min: 0.26   Max: 4.42
Current: 1.9

0.26
4.42
EV-to-EBIT 500.00
QLTI's EV-to-EBIT is ranked lower than
85% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. QLTI: 500.00 )
QLTI' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 181.7
Current: 500

0.1
181.7
Shiller P/E 10.60
QLTI's Shiller P/E is ranked higher than
95% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. QLTI: 10.60 )
QLTI' s 10-Year Shiller P/E Range
Min: 10.2   Max: 272.75
Current: 10.6

10.2
272.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.70
QLTI's Price/Net Cash is ranked higher than
90% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. QLTI: 2.70 )
QLTI' s 10-Year Price/Net Cash Range
Min: 1.38   Max: 28.13
Current: 2.7

1.38
28.13
Price/Net Current Asset Value 2.60
QLTI's Price/Net Current Asset Value is ranked higher than
90% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. QLTI: 2.60 )
QLTI' s 10-Year Price/Net Current Asset Value Range
Min: 1.33   Max: 25.32
Current: 2.6

1.33
25.32
Price/Tangible Book 1.90
QLTI's Price/Tangible Book is ranked higher than
89% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. QLTI: 1.90 )
QLTI' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 21.1
Current: 1.9

0.56
21.1
Price/DCF (Projected) 4.80
QLTI's Price/DCF (Projected) is ranked lower than
53% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. QLTI: 4.80 )
QLTI' s 10-Year Price/DCF (Projected) Range
Min: 0.44   Max: 44.58
Current: 4.8

0.44
44.58
Forward Rate of Return (Yacktman) -0.95
QLTI's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. QLTI: -0.95 )
QLTI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 11.9
Current: -0.95

-2
11.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QLT.Canada, QLT.Germany
QLT, Inc., was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company is developing its synthetic retinoid program for the treatment of certain inherited retinal diseases. Its competitors include major pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide